KOD Kodiak Sciences Inc

18.85
+1.21  (+7%)
Previous Close 17.64
Open 17.52
Price To Book 9.92
Market Cap 696,152,008
Shares 36,931,141
Volume 461,606
Short Ratio
Av. Daily Volume 200,367
Stock charts supplied by TradingView

NewsSee all news

  1. Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  2. Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301.

  3. Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

    PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,

  4. Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

    PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  5. Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 pivotal trial commencement of dosing announced October 10, 2019 with interim data 2020 and final data 2021.
KSI-301
Wet age-related macular degeneration (AMD)
Phase 1b data to be presented at the Retina Subspecialty Day October 11, 2019.
KSI-301
Diabetic macular edema (DME)

Latest News

  1. Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  2. Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301.

  3. Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

    PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,

  4. Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

    PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  5. Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  6. Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  7. Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference

    PALO ALTO, Calif., Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  8. Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

    PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today